Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) EBT Margin (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of EBT Margin readings, the most recent being 928.47% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 8758.0% to 928.47% in Q1 2026 year-over-year; TTM through Feb 2026 was 431.09%, a 34337.0% decrease, with the full-year FY2025 number at 184.02%, up 1576.0% from a year prior.
  • EBT Margin reached 928.47% in Q1 2026 per CBIH's latest filing, down from 186.06% in the prior quarter.
  • The five-year high for EBT Margin was 24.08% in Q2 2024, with the low at 1016.05% in Q1 2025.
  • A 5-year average of 413.01% and a median of 323.53% in 2025 define the central range for EBT Margin.
  • Year-over-year, EBT Margin skyrocketed 61898bps in 2024 and then plummeted -70394bps in 2025.
  • Year by year, EBT Margin stood at 266.27% in 2022, then soared by 44bps to 148.26% in 2023, then surged by 38bps to 92.03% in 2024, then tumbled by -102bps to 186.06% in 2025, then tumbled by -399bps to 928.47% in 2026.
  • Per Business Quant, the three most recent readings for CBIH's EBT Margin are 928.47% (Q1 2026), 186.06% (Q4 2025), and 380.79% (Q3 2025).